New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > SKIN BCC Metastatic - vismodegib

SKIN BCC Metastatic - vismodegib

Treatment Overview

Cycle 1 (and all further cycles) - 28 days

Cycle length:
28

Cycle details

Cycle 1 (and all further cycles) - 28 days

Medication Dose Route Days Max Duration
vismodegib 150 mg Once daily oral administration 1 to 28
domperidone 10 mg Three times daily oral administration 1

Full details

Cycle 1 (and all further cycles) - 28 days

Day: 1

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.
domperidone 10 mg Three times daily oral administration
Instructions:
When required for nausea and/or vomiting. The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics.

Day: 2

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 3

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 4

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 5

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 6

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 7

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 8

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 9

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 10

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 11

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 12

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 13

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 14

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 15

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 16

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 17

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 18

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 19

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 20

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 21

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 22

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 23

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 24

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 25

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 26

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 27

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Day: 28

Medication Dose Route Max duration Details
vismodegib 150 mg Once daily oral administration
Instructions:
Take with a glass of water and swallow whole, do not crush or chew.

Supportive Care Factors

Factor Value
Emetogenicity: Low

References

Sekulic, A., M. R. Migden, A. E. Oro, et al. 2012. "Efficacy and safety of vismodegib in advanced basal-cell carcinoma." N Engl J Med 366(23):2171-2179 , PMID: 22670903

Sekulic, A., M. R. Migden, K. Lewis, et al. 2015. "Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC." J Am Acad Dermatol 72(6):1021-1026.e1028. , PMID: 25981002

Dreno, B., R. Kunstfeld, A. Hauschild, et al. 2017. "Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial." Lancet Oncol 18(3):404-412. , PMID: 28188086

Roche Products (New Zealand) Limited. Erivedge New Zealand Data Sheet 26 February 2020. https://www.medsafe.govt.nz/profs/Datasheet/e/erivedgecap.pdf (Accessed 14 June 2021).

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.